Harnessing exDNA for precision exatecan delivery in cancer: a novel antibody-drug conjugate approach
Zaira Ianniello(Yale University), Peter M. Glazer(Yale University)
Cited by 3
Related Papers
Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
|Molecular Cancer Therapeutics|2011|206
In vivo correction of anaemia in β-thalassemic mice by γPNA-mediated gene editing with nanoparticle delivery
|Nature Communications|2016|183
Potentiation of Temozolomide Cytotoxicity by Inhibition of DNA Polymerase β Is Accentuated by BRCA2 Mutation
|Cancer Research|2009|34